Routine double-ovarian-stimulation (DuoStim) in poor responders lacks rationale, evidence, and follow-up
- PMID: 36692185
- DOI: 10.1093/humrep/dead002
Routine double-ovarian-stimulation (DuoStim) in poor responders lacks rationale, evidence, and follow-up
Abstract
Double ovarian stimulation (DuoStim), initially only suggested for fertility preservation in cancer patients, is now increasingly also used in routine clinical IVF, especially in poor responders. The claimed rational for this is the alleged existence of multiple follicular waves in a single intermenstrual interval, allowing for retrieval of more oocytes in a single IVF cycle. This commentary argues that this expansion of purpose lacks rationale, evidence, and follow-up. Consequently, we suggest that, unless valid clinical indications have been established, DuoStim be only subject of controlled clinical trials with appropriate experimental consents.
Keywords: DuoStim; IVF-ET; double-ovarian-stimulation; evidence; follow-up; live birth rate; ovarian stimulation; poor ovarian response; rational.
© The Author(s) 2023. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Comment in
-
Reply: The discussion surrounding DuoStim is resolved.Hum Reprod. 2023 Aug 1;38(8):1644-1645. doi: 10.1093/humrep/dead114. Hum Reprod. 2023. PMID: 37352217 No abstract available.
-
DuoStim reduces time to pregnancy, minimizes treatment discontinuation, and is potentially cost-effective.Hum Reprod. 2023 Aug 1;38(8):1643-1644. doi: 10.1093/humrep/dead113. Hum Reprod. 2023. PMID: 37352226 No abstract available.
MeSH terms
LinkOut - more resources
Full Text Sources
